Loading...
PSG logo

PharmaSGP Holding SEXTRA:PSG Stock Report

Market Cap €345.4m
Share Price
€29.00
€39.5
26.6% undervalued intrinsic discount
1Y43.6%
7D0%
Portfolio Value
​
View

PharmaSGP Holding SE

XTRA:PSG Stock Report

Market Cap: €345.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

PharmaSGP Holding (PSG) Stock Overview

Manufactures and sells over-the-counter drugs and other healthcare products in Germany. More details

PSG fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends3/6

Rewards

Trading at 25.5% below our estimate of its fair value

Earnings have grown 9.8% per year over the past 5 years

Risk Analysis

Has a high level of debt


PSG Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 72.0% undervalued intrinsic discount
5022.2%Revenue growth p.a.
2.7k
19
0
30
16d ago

PharmaSGP Holding SE Competitors

Price History & Performance

Summary of share price highs, lows and changes for PharmaSGP Holding
Historical stock prices
Current Share Price€29.00
52 Week High€30.00
52 Week Low€19.00
Beta-0.033
1 Month Change1.40%
3 Month Change7.41%
1 Year Change43.56%
3 Year Change18.37%
5 Year Change-6.45%
Change since IPO-15.94%

Recent News & Updates

Recent updates

PharmaSGP Holding's (ETR:PSG) Performance Is Even Better Than Its Earnings Suggest

Dec 06
PharmaSGP Holding's (ETR:PSG) Performance Is Even Better Than Its Earnings Suggest

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

May 06
Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Mar 02
Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Dec 02
PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

Feb 16
One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Jan 26
We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Dec 04
Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Shareholder Returns

PSGDE PharmaceuticalsDE Market
7D0%4.4%3.3%
1Y43.6%28.4%11.2%

Return vs Industry: PSG exceeded the German Pharmaceuticals industry which returned -24.7% over the past year.

Return vs Market: PSG exceeded the German Market which returned 18.2% over the past year.

Price Volatility

Is PSG's price volatile compared to industry and market?
PSG volatility
PSG Average Weekly Movement2.5%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement6.1%
10% most volatile stocks in DE Market13.7%
10% least volatile stocks in DE Market2.6%

Stable Share Price: PSG has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: PSG's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201991Peter Gerckenspharmasgp.com

PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo.

PharmaSGP Holding SE Fundamentals Summary

How do PharmaSGP Holding's earnings and revenue compare to its market cap?
PSG fundamental statistics
Market cap€345.38m
Earnings (TTM)€19.71m
Revenue (TTM)€122.10m
17.5x
P/E Ratio
2.8x
P/S Ratio

Is PSG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PSG income statement (TTM)
Revenue€122.10m
Cost of Revenue€11.54m
Gross Profit€110.56m
Other Expenses€90.85m
Earnings€19.71m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Sep 11, 2025

Earnings per share (EPS)1.71
Gross Margin90.55%
Net Profit Margin16.14%
Debt/Equity Ratio178.5%

How did PSG perform over the long term?

See historical performance and comparison

Dividends

1.7%
Current Dividend Yield
30%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/23 05:38
End of Day Share Price 2025/08/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmaSGP Holding SE is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard OrgonasBerenberg
Charles WestonRBC Capital Markets
Jack Reynolds-ClarkRBC Capital Markets